Summary:
The submitted prospective study compares the results of two therapeutic approaches in 60 patients with mammary cancer of the stage T1-2a No — 1a MO, followed — up for an average period of 86 months. 31 patients were treated by surgical operation alone (mastectomy with exenteration of the axilla and revision with extirpation of the nodes in the area of the internal mammary artery in tumours localized in median quadrants). In 29 patients during the third week after the same operation long — term immunotherapy with BCG vaccine was started — using the Pasteur scarification method (3,75 —32.107 viable units per dose, during the first three months once a week, during the subsequent 9 months once in six weeks and then up to three years after mastectomy once in 6 months). The authors did not find a difference in the incidence of progression of the disease and deaths as a result of progression between the two groups.
Non-specific active immunotherapy with the BCG vaccine in patients with breast carcinoma. Evaluation after 7 year follow-up
